Immunovant CEO receives stock option and RSU awards
Immunovant, Inc. Chief Executive Officer Eric Venker received new equity awards as compensation.
Rhea-AI Filing Summary
Immunovant, Inc. Chief Executive Officer Eric Venker received new equity awards as compensation. He was granted stock options covering 336,043 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036.
He also received 232,252 restricted stock units, each representing one share of common stock upon vesting. The options and RSUs vest 25% on April 1, 2027, with the remaining amounts vesting in regular installments thereafter, contingent on his continuous service. Following the RSU grant, he directly holds 251,813 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 568,295 shares
Grant/Award
2 txns
Insider
Venker Eric
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 336,043 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 232,252 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 336,043 contracts (Direct);
Common Stock — 251,813 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
Options granted: 336,043 shares
Option exercise price: $24.61 per share
Option expiration: April 7, 2036
+3 more
6 metrics
Options granted
336,043 shares
Stock options on common stock granted April 7, 2026
Option exercise price
$24.61 per share
Exercise price for 336,043 stock options
Option expiration
April 7, 2036
Expiration date of granted stock options
RSUs granted
232,252 units
Restricted stock units granted under 2019 Equity Incentive Plan
Initial vesting date
April 1, 2027
25% of RSUs and options vest on this date
Common shares held
251,813 shares
Total common stock directly owned after RSU grant
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, Stock Option (right to buy), continuous service, +1 more
5 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")"
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer as of such date"
vesting financial
"The RSUs will vest as to 25% of the total shares on April 1, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immunovant (IMVT) CEO Eric Venker acquire in this Form 4 filing?
Eric Venker received option and RSU grants as compensation, not open-market purchases. He was granted options on 336,043 shares and 232,252 restricted stock units, both tied to future vesting and continued service with Immunovant.
What are the key terms of Eric Venker’s new stock options at Immunovant (IMVT)?
The options cover 336,043 shares of Immunovant common stock at an exercise price of $24.61 per share. They expire on April 7, 2036 and vest over time, starting in 2027, subject to his continued service.
How do the RSUs granted to Immunovant (IMVT) CEO Venker vest?
The 232,252 RSUs vest as to 25% of the shares on April 1, 2027. The remaining units vest in twelve substantially equal quarterly installments afterward, conditioned on his continuous service with Immunovant through each vesting date.
Are Eric Venker’s new equity awards at Immunovant (IMVT) open-market buys or compensation grants?
They are compensation grants, not open-market buys. The Form 4 uses transaction code “A” for grant or award, with a zero purchase price, and footnotes explain these are awards under Immunovant’s 2019 Equity Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
